raig daniels
Cancer
+ HIPEC
Watch: CRS + HIPEC Explained
What Is CRS + HIPEC?
CRS + HIPEC is a two-part procedure performed in a single operation. It is one of the few surgical options with curative intent for peritoneal surface malignancies — cancers that have spread to the peritoneum, the thin tissue lining that covers the abdominal cavity and most of the organs inside it.
The two parts work in sequence. First, the surgeon removes every visible tumor from the peritoneal surface — that is the cytoreductive surgery (CRS). Then, before the abdomen is closed, a heated chemotherapy solution is circulated directly inside the abdominal cavity for 60 to 120 minutes — that is the HIPEC.
The combination is deliberate. Surgery handles what can be seen and physically removed. HIPEC handles what cannot — microscopic disease, loose cells, tumor deposits too small to detect or resect.
Part One: Cytoreductive Surgery (CRS)
Cytoreductive surgery is exactly what it sounds like — reducing the tumor burden. The goal is a complete cytoreduction, meaning no visible tumor remains. Surgeons use the term CC-0 to describe this outcome. CC-1 means residual nodules under 2.5mm remain. Anything above that significantly reduces the benefit of the HIPEC that follows.
To achieve complete cytoreduction, the surgeon may need to remove affected sections of bowel, the omentum (the fatty apron covering the abdominal organs), parts of the diaphragm, the spleen, portions of the liver surface, and the peritoneal lining itself from multiple abdominal regions. The extent of resection is driven entirely by where the tumor has spread.
The scope of the operation is assessed using the Peritoneal Cancer Index (PCI) — a scoring system that divides the abdomen into 13 regions and assigns each a score of 0 to 3 based on tumor size. A PCI of 0 means no visible disease. The maximum score is 39. For colorectal peritoneal metastases, most high-volume centers consider a PCI under 20 a reasonable threshold for proceeding with surgery, though this is surgeon- and institution-dependent.
CRS alone is not a short operation. Depending on disease burden, it typically runs between 6 and 12 hours before HIPEC begins.
Part Two: HIPEC
Once cytoreduction is complete, the HIPEC phase begins. The abdomen is temporarily closed or held open, and a pump circulates a heated chemotherapy solution — typically between 41°C and 43°C — through the peritoneal cavity via inflow and outflow catheters.
The heat is not incidental. It serves two functions. First, it enhances the cytotoxicity of the chemotherapy agent — heat makes cancer cells more permeable and more vulnerable to the drug. Second, heat itself has a direct anti-tumor effect at temperatures in this range, damaging cancer cells while sparing most normal tissue.
Delivering chemotherapy this way — directly into the abdomen rather than through the bloodstream — also means dramatically higher local drug concentrations with significantly lower systemic exposure. The peritoneum acts as a barrier. The drug does its work where the disease is, and far less of it enters general circulation.
The most commonly used agents for colorectal peritoneal metastases are mitomycin C and oxaliplatin, though protocols vary by institution and by the patient's prior treatment history. Duration of perfusion is typically 60 to 120 minutes depending on the agent and center protocol.
After perfusion is complete, the solution is drained, the abdomen is irrigated, and the surgeon closes.
Who Is a Candidate?
Patient selection is the single most important factor in outcomes. CRS + HIPEC is a major operation with a significant complication profile. Performed on the wrong patient, it offers no benefit and substantial harm. Performed on the right patient at the right center, it offers the possibility of long-term survival and, in some cases, cure.
The general criteria for candidacy include:
Disease factors: Peritoneal metastases that are limited in extent (low to moderate PCI), confined to the peritoneal surface with no extraperitoneal disease (no liver parenchymal metastases, no lung metastases, no distant nodal disease), and disease that has responded — or is stable — on systemic chemotherapy.
Patient factors: Performance status adequate to tolerate a major operation, no significant organ dysfunction, and nutritional status sufficient to support recovery from extended surgery.
Technical factors: A surgical team's assessment that complete or near-complete cytoreduction (CC-0 or CC-1) is achievable. If complete cytoreduction is not feasible, the case for proceeding becomes difficult to justify for most histologies.
For colorectal-origin peritoneal metastases specifically, evidence from randomized data — particularly the PRODIGE 7 trial — has clarified the role of HIPEC and reinforced that patient selection and complete cytoreduction drive outcomes more than the HIPEC agent or protocol alone.
Recovery
Recovery from CRS + HIPEC is substantial. It is not a procedure patients bounce back from in days. The combination of extended operating time, multi-visceral resection, and intraperitoneal chemotherapy creates a significant physiological load.
Hospital stays typically run 10 to 14 days for uncomplicated cases, often longer. The first few days post-operatively are managed in an ICU or high-dependency setting. Return of bowel function, wound healing, and nutritional recovery are the primary milestones before discharge.
Full recovery — returning to baseline activity and function — is measured in months, not weeks. Most centers estimate 6 to 8 weeks before patients are mobile and functioning at a reasonable level. Full functional recovery often takes 3 to 6 months depending on the extent of resection and individual response.
Complication rates at experienced centers run approximately 25–35% for major complications, with a 30-day mortality rate under 5% at high-volume programs. These numbers are not intended to alarm — they reflect the complexity of the procedure and underscore why volume and experience at the operating center matter as much as the surgery itself.
Why This Page Exists
I have metachronous peritoneal carcinomatosis from cecal adenocarcinoma. CRS + HIPEC is the treatment I am working toward. This page is part of how I document and share what I have learned in the process of evaluating surgical centers, reviewing the literature, and deciding who I want holding the scalpel.
If you found this page because you or someone you know is in a similar position — working through what this surgery means and whether it applies to your situation — I hope it gives you a useful starting point. The research trail is long. Start here, then go deeper.